SEC Form 4 · accession 0001209191-16-131336

Lineage Cell Therapeutics, Inc. · LCTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — See Remarks · Director

Period of report

Jul 1, 2016

Accepted (ET)

Jul 5, 2016 · 7:45 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000876343

Table I — non-derivative securities

Security	Date	Code	Shares	A/D	Owned after	D/I	Nature of ownership
Common Shares, no par value^F1	holding	—	—	—	5,931,555	D
Common Shares, no par value	holding	—	—	—	1,451,105	I	By Greenbelt Corp.
Common Shares, no par value	holding	—	—	—	375,351	I	By Greenway Partners, LP

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Option to Purchase Common Shares^F2	$2.72	Jul 1, 2016	A	50,000	A	—	Jun 30, 2021	Common Shares	50,000	50,000	D
Option to Purchase Common Shares^F3	$3.57	holding	—	—	—	—	Jun 30, 2020	Common Shares	50,000	50,000	D
Option to Purchase Common Shares^F4	$3.11	holding	—	—	—	—	Jun 30, 2019	Common Shares	50,000	50,000	D
Option to Purchase Common Shares^F5	$4.13	holding	—	—	—	—	Jun 30, 2018	Common Shares	50,000	50,000	D
Option to Purchase Common Shares^F6	$4.60	holding	—	—	—	—	Jun 30, 2017	Common Shares	50,000	50,000	D

F1Does not include shares that Mr. Kingsley may acquire through the exercise of certain options.
F2Will become exercisable in four equal quarterly installments based upon continued service on the board of directors.
F3Became exercisable in four equal quarterly installments after the date of grant on July 1, 2015.
F4Became exercisable in four equal quarterly installments after the date of grant on July 1, 2014.
F5Became exercisable in four equal quarterly installments after the date of grant on July 1, 2013.
F6Became exercisable in four equal quarterly installments after the date of grant on July 1, 2012.

Mr. Kingsley is Chairman of certain BioTime subsidiaries.